ZA201708613B - Antibodies that bind to sortilin and inhibit the binding of progranulin - Google Patents

Antibodies that bind to sortilin and inhibit the binding of progranulin

Info

Publication number
ZA201708613B
ZA201708613B ZA2017/08613A ZA201708613A ZA201708613B ZA 201708613 B ZA201708613 B ZA 201708613B ZA 2017/08613 A ZA2017/08613 A ZA 2017/08613A ZA 201708613 A ZA201708613 A ZA 201708613A ZA 201708613 B ZA201708613 B ZA 201708613B
Authority
ZA
South Africa
Prior art keywords
progranulin
sortilin
antibodies
bind
inhibit
Prior art date
Application number
ZA2017/08613A
Other languages
English (en)
Inventor
Christian Biilmann Rønn Lars
John Malik Ibrahim
B Stavenhagen Jeffrey
Christensen Søren
Egebjerg Jan
Gerritsen Arnout
Van Den Brink Edward
Parren Paul
De Jong Rob
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ZA201708613B publication Critical patent/ZA201708613B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2017/08613A 2015-07-13 2017-12-18 Antibodies that bind to sortilin and inhibit the binding of progranulin ZA201708613B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1512215.3A GB201512215D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
PCT/EP2016/066516 WO2017009327A1 (en) 2015-07-13 2016-07-12 Antibodies that bind to sortilin and inhibit the binding of progranulin

Publications (1)

Publication Number Publication Date
ZA201708613B true ZA201708613B (en) 2021-03-31

Family

ID=54013862

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/08613A ZA201708613B (en) 2015-07-13 2017-12-18 Antibodies that bind to sortilin and inhibit the binding of progranulin

Country Status (35)

Country Link
US (6) US10479835B2 (enExample)
EP (1) EP3322726B1 (enExample)
JP (2) JP6979397B2 (enExample)
KR (1) KR102778576B1 (enExample)
CN (3) CN107849135A (enExample)
AR (1) AR105335A1 (enExample)
AU (1) AU2016292980B2 (enExample)
BR (1) BR112018000771A2 (enExample)
CA (1) CA2989739A1 (enExample)
CL (2) CL2018000092A1 (enExample)
CO (1) CO2017012988A2 (enExample)
CR (1) CR20180002A (enExample)
DO (1) DOP2018000014A (enExample)
EA (1) EA201890038A1 (enExample)
EC (1) ECSP18002725A (enExample)
ES (1) ES3024469T3 (enExample)
GB (1) GB201512215D0 (enExample)
HR (1) HRP20250602T1 (enExample)
HU (1) HUE071424T2 (enExample)
IL (1) IL256503B (enExample)
JO (1) JO3710B1 (enExample)
MA (1) MA42440B1 (enExample)
MX (1) MX2018000506A (enExample)
NI (1) NI201800007A (enExample)
PE (1) PE20181014A1 (enExample)
PH (1) PH12018500100A1 (enExample)
PL (1) PL3322726T3 (enExample)
RS (1) RS66856B1 (enExample)
RU (1) RU2735639C2 (enExample)
SV (1) SV2018005613A (enExample)
TN (1) TN2017000534A1 (enExample)
TW (1) TWI760305B (enExample)
UA (1) UA125136C2 (enExample)
WO (1) WO2017009327A1 (enExample)
ZA (1) ZA201708613B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2899227T3 (es) * 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR102530517B1 (ko) * 2018-07-13 2023-05-09 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1
MX2022007486A (es) * 2019-12-23 2022-06-29 Denali Therapeutics Inc Variantes de progranulina.
EP4171743A4 (en) 2020-06-24 2024-07-24 Prothena Biosciences Limited Antibodies recognizing sortilin
JP2025530891A (ja) 2022-06-23 2025-09-18 ドラウプニル バイオ エーピーエス リソソーム内の細胞外標的の分解を選択的に誘導する二機能性分子
CN118496354A (zh) * 2023-02-15 2024-08-16 三优生物医药(上海)有限公司 包含共同轻链的抗体库、其制备方法及其用途
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用
WO2025132764A1 (en) * 2023-12-21 2025-06-26 Amylonix Ab A sortilin-binding polypeptide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
HK1049014A1 (zh) 1999-07-29 2003-04-25 Medarex, Inc. 抗her2/neu的人类单克隆抗体
DK1212422T3 (da) 1999-08-24 2007-07-02 Medarex Inc Humane CTLA-4-antistoffer og anvendelserne deraf
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
DK2120997T3 (en) * 2006-12-21 2017-05-08 H Lundbeck As MODULATION OF PRO-NEUROTROPHIN ACTIVITY
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
EP2293667A4 (en) 2008-05-27 2012-07-18 Kyowa Hakko Kirin Co Ltd INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3165537A1 (en) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
RU2536232C2 (ru) * 2011-07-01 2014-12-20 Олег Ильич Эпштейн Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
WO2014071131A1 (en) 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
ES2899227T3 (es) 2015-04-07 2022-03-10 Alector Llc Anticuerpos anti sortilina y métodos de uso de los mismos
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
KR102530517B1 (ko) 2018-07-13 2023-05-09 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법

Also Published As

Publication number Publication date
JP6979397B2 (ja) 2021-12-15
TN2017000534A1 (en) 2019-04-12
CL2020002468A1 (es) 2021-01-29
US20200190188A1 (en) 2020-06-18
JP2022003058A (ja) 2022-01-11
US12331123B2 (en) 2025-06-17
EA201890038A1 (ru) 2018-06-29
EP3322726B1 (en) 2025-03-12
BR112018000771A2 (pt) 2018-09-25
PE20181014A1 (es) 2018-06-26
CN107849135A (zh) 2018-03-27
RU2735639C2 (ru) 2020-11-05
TW201702273A (zh) 2017-01-16
JO3710B1 (ar) 2021-01-31
IL256503B (en) 2022-02-01
US11548950B2 (en) 2023-01-10
KR20180030045A (ko) 2018-03-21
RS66856B1 (sr) 2025-06-30
NI201800007A (es) 2018-10-18
TWI760305B (zh) 2022-04-11
US10479835B2 (en) 2019-11-19
UA125136C2 (uk) 2022-01-19
CL2018000092A1 (es) 2018-07-06
PL3322726T3 (pl) 2025-06-23
AU2016292980B2 (en) 2022-10-06
MA42440A (fr) 2018-05-23
US20180305455A1 (en) 2018-10-25
AR105335A1 (es) 2017-09-27
US10889650B2 (en) 2021-01-12
RU2018100824A (ru) 2019-08-13
HUE071424T2 (hu) 2025-08-28
KR102778576B1 (ko) 2025-03-07
EP3322726A1 (en) 2018-05-23
ECSP18002725A (es) 2018-03-31
WO2017009327A1 (en) 2017-01-19
CR20180002A (es) 2018-04-09
RU2018100824A3 (enExample) 2020-01-17
JP2018529635A (ja) 2018-10-11
GB201512215D0 (en) 2015-08-19
CA2989739A1 (en) 2017-01-19
AU2016292980A1 (en) 2018-01-18
US20170267761A1 (en) 2017-09-21
CO2017012988A2 (es) 2018-05-21
SV2018005613A (es) 2018-02-23
US20250277040A1 (en) 2025-09-04
CN114478774A (zh) 2022-05-13
US20230159643A1 (en) 2023-05-25
MA42440B1 (fr) 2025-05-30
HK1254356A1 (en) 2019-07-19
DOP2018000014A (es) 2018-04-15
MX2018000506A (es) 2018-05-11
US10428147B2 (en) 2019-10-01
US20210269524A1 (en) 2021-09-02
IL256503A (en) 2018-02-28
CN114478775A (zh) 2022-05-13
EP3322726C0 (en) 2025-03-12
HRP20250602T1 (hr) 2025-07-18
PH12018500100A1 (en) 2018-07-30
ES3024469T3 (en) 2025-06-04

Similar Documents

Publication Publication Date Title
IL256503B (en) Antibodies that bind sortilin and inhibit binding to progranulin
IL284336B (en) Treatment using antibodies that bind to ctla4
IL267113A (en) Antibodies that specifically bind to human IL-15 and their uses
ZA201803669B (en) Antibodies specifically binding pd-1 and their uses
IL252467A0 (en) Heterodimeric antibodies that bind cd3 and cd38
IL248007A0 (en) Bispecific antibodies that bind to cd38 and cd3
ZA201708589B (en) Factor xi antibodies and methods of use
ZA201707138B (en) Anti-ceacam6 antibodies and uses thereof
ZA201801427B (en) Antibodies that specifically bind to tl1a
IL256295A (en) Anti-ntb-a antibodies and related compositions and methods
IL251676A0 (en) Antibodies that bind to ccr6 and their uses
SG11201704500VA (en) Antibody binding to neuropilin 1 and use thereof
PL3362480T3 (pl) Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie